Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T15:05:46.011Z.
Consensus retrieved: 2026-10-06T09:12:28.532Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:05:46.011Z.
Quote observation: 2026-10-06T15:05:20.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6a2f90c369cc2bba861e7882df5fb589e6a534c6c6a3ec3aca589af2a274c9b5
Forward PE Ratio (N/A) = Dated Quote Price ($7.16) / Consensus Forward EPS ($-1.23)
FORWARD PE RATIO
N/A
Anteris Technologies Global Corp.
Market Cap
$696.18M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Anteris Technologies Global Corp. (AVR) | $696.18M | N/A |
| Faeth Therapeutics, Inc. (FTH)vs › | $708.93M | N/A |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $709.16M | N/A |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $711.06M | N/A |
| Annexon, Inc. (ANNX)vs › | $679.13M | N/A |
| Helus Pharma Inc. (HELP)vs › | $671.29M | N/A |
| Avalo Therapeutics, Inc. (AVTX)vs › | $719.62M | N/A |
| Cytek Biosciences, Inc. (CTKB)vs › | $721.26M | N/A |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $665.48M | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $665.40M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $7.16, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-1.23 | $-1.24 – $-1.21 | 2 | n/m |
| 2027-12-31 | $-1.13 | $-1.34 – $-0.91 | 2 | n/m |
| 2028-12-31 | $-0.82 | $-1.57 – $-0.04 | 1 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
